Advertisement

Urgences hématologiques et oncologiques

Chapter
  • 710 Downloads

Résumé

Déf.: Développement d’une infection (processus septique) chez un patient neutropénique (dans le contexte d’une chimiothérapie ou d’une radiothérapie)
  • Sepsis: température > 38,0 °C ou < 36 °C, fréquence cardiaque > 90/min, fréquence respiratoire > 20/min ou PaCO2 < 32 mmHg.

  • Choc septique: hypotension avec tension artérielle (TA) < 90 mmHg (systolique) ou réduction de TA de 40 mmHg et signes de défaillance d’organe: acidose lactique, oligurie, défaillance multiviscérale (DMV).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453PubMedCrossRefGoogle Scholar
  2. 2.
    Bertz H, Auner HW, Weissinger F et al. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation: guidelines of the AGIHO/DGHO. Ann Hematol 2003;82(suppl 2):S167–174PubMedCrossRefGoogle Scholar
  3. 3.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences and new directions for its management. Cancer 2004;100:228–237PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Recommendations for the application. Ann Oncol 2007;18(Suppl.2):ii89–91Google Scholar
  5. 5.
    Penack O, Beinert T, Buchheidt D et al. Management of sepsis in neutropenia: guidelines of the AGIHO/DGHO. Ann Hematol 2006;85:424–433PubMedCrossRefGoogle Scholar
  6. 6.
    Sipsas NV, Bodey GP, Kostoyiannis DP. Perspectives for the management of febrile neutropenic patients. Cancer 2005;103:1103–1113PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TJ, Khatcheressian J, Lyman GJ et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Aurora R, Milite F, Vander Els NJ. Respiratory emergencies. Semin Oncol 2000;27:256–269PubMedGoogle Scholar
  2. 2.
    Kanani RS, Drachmann DE. Malignant obstruction of the superior vena cava. N Engl J Med 2006;354:e7PubMedCrossRefGoogle Scholar
  3. 3.
    Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001;CD001316Google Scholar
  4. 4.
    Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007;356:1862–1869PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bagley CA, Gokaslan ZL. Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus 2004;16:e3PubMedCrossRefGoogle Scholar
  2. 2.
    Byrne T. Spinal cord compression from epidural metastases. N Engl J Med 1992;327:614–617PubMedCrossRefGoogle Scholar
  3. 3.
    Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence based guideline. J Clin Oncol 1998;16:1613–1624PubMedGoogle Scholar
  4. 4.
    Maranzano E, Bellavita R, Rossi R et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005;23:3358–3365PubMedCrossRefGoogle Scholar
  5. 4.
    Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin Oncol 2000;27:311–321PubMedGoogle Scholar

Réf.

  1. 1.
    Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000;27:244–255PubMedGoogle Scholar
  2. 2.
    Little WC, Freeman GL. Pericardial disease. Circulation 2006;113:1622–1632PubMedCrossRefGoogle Scholar
  3. 3.
    Martinoni A, Cipolla CM, Civelli M et al. Intrapericardial treatment of neoplastic pericardial effusions. Herz 2000;25:787–793PubMedCrossRefGoogle Scholar
  4. 4.
    Retter AS. Pericardial disease in the oncology patient. Heart Dis 2002;4:387–391PubMedCrossRefGoogle Scholar
  5. 5.
    Soler-Soler J, Sagrista-Sauleda J, Permanyer-Miralda G. Management of pericardial effusion. Heart 2001;86:235–240PubMedCrossRefGoogle Scholar
  6. 6.
    Spodick DH. Acute cardiac tamponade. N Engl J Med 2003;349:684–690PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bajorunas DR. Clinical manifestations of cancer-related hypercalcemia. Semin Oncol 1990;17:16–20PubMedGoogle Scholar
  2. 2.
    Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000;27:322–334PubMedGoogle Scholar
  3. 3.
    Perry CM, Figgitt DP. Zoledronic acid. Drugs 2004;64:1197–1211PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373–379PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Hematol 2004;127:3–11CrossRefGoogle Scholar
  2. 2.
    Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition and alternative treatment approaches. Clin Adv Hematol Oncol 2005;3:54–61PubMedGoogle Scholar
  3. 3.
    Nicolin G. Emergencies and their management. Eur J Cancer 2002;38:1365–1377PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006;135:634–641CrossRefGoogle Scholar
  2. 2.
    Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol 2005;3:102–110Google Scholar
  3. 3.
    Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301–2311PubMedCrossRefGoogle Scholar
  4. 4.
    Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004;9:561–570PubMedCrossRefGoogle Scholar
  5. 5.
    Reimann T, Butts CA. Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature. Can J Gastroenterol 2001;15:67–71Google Scholar

Réf.

  1. 1.
    Davenport DD. Pathophysiology of hemolytic transfusion reactions. Semin Hematol 2005;42:165–169PubMedCrossRefGoogle Scholar
  2. 2.
    Dzik WH. New technology for transfusion safety. Br J Haematol 2006;136:181–190PubMedCrossRefGoogle Scholar
  3. 3.
    Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections 2003. Curr Opin Hematol 2003;10:412–418PubMedCrossRefGoogle Scholar
  4. 4.
    Popovsky MA (ed). Transfusion Reactions, 2nd edn. AABB Press, Bethesda, USA, 2001Google Scholar
  5. 5.
    Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002;117:257–287CrossRefGoogle Scholar
  6. 6.
    Sillmann CC, Ambrusi DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266–2273CrossRefGoogle Scholar

Réf.

  1. 1.
    Davies AG, Russell WC, Thompson JP. Extravasation and tissue necrosis due to central line infusions. Anaesthesia 2003;58:820–821PubMedCrossRefGoogle Scholar
  2. 2.
    Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858–862PubMedCrossRefGoogle Scholar
  3. 3.
    Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006;33:139–142PubMedCrossRefGoogle Scholar
  4. 4.
    Kurul SP, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 2002;3:684–692PubMedCrossRefGoogle Scholar
  5. 5.
    Napoli P, Corradino B, Badalamenti G et al. Surgical treatment of extravasation injuries. J Surg Oncol 2005;91:264–268PubMedCrossRefGoogle Scholar
  6. 6.
    Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol 2003;14(suppl 3):iii26–30PubMedGoogle Scholar
  7. 7.
    Schulmeister L. Managing vesicant extravasations. Oncologist 2008;13:284–288PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations